omniture
沙砾生物

Latest News

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics adva...

2025-12-06 22:45 1898

Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801

BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio "), a leading clinic...

2025-11-04 21:15 1487

Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting

SHANGHAI, May 29, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio "), a clinical-stage ...

2025-05-29 20:30 1739

Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting

SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio "), a clinical-stage ...

2025-05-12 20:30 2304

GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer

SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading comp...

2025-01-03 15:30 3284

GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2

SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Qu...

2024-05-31 21:16 3216

Grit Biotechnology Announces Closing of $60 Million Series B Financing

SHANGHAI, Sept. 8, 2023 /PRNewswire/ -- On September 8, 2023, Grit Biotechnology announced the comp...

2023-09-08 17:00 2936